anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain the subject new compound capable of exhibiting excellent herbicidal, plant disease-containing, antitumor, antiarteriosclerotic, immunosuppressive and bronchodilation activities and useful as a medicine or an agricultural chemical by culturing a specific mold. SOLUTION: The subject compound is expressed by the formula. The compound is useful as an agricultural chemical (herbicide, plant disease-controlling agent, etc.), or a medicine (antitumor agent, antiasthmatic agent, antiarteriosclerotic agent, antiallergic agent, antirheumatic agent, etc.). The compound is obtained by culturing a non-identified strain No-155 (FERM P-16083) at a temperature of 20-28 deg.C at a pH of 5.0-8.0 usually for 8-16 days under an aerobic condition and subsequently isolating the compound from the culture product. When used as a herbicide or a plant disease-controlling agent, the compound is applied at a dose of 0.001-10 kg/ha. When used as an antitumor, the compound is administered at a daily dose of 0.01-100 mg/kg body.
They received boluses of lornoxicam 0.8 mg/mL before induction of anaesthesia followed by a 12 hourly boluses of 0.9% saline and a constant infusion at 10 mL/h of lornoxicam 0.13 mg/mL, for 48 hrs. after surgery.
An example of a system for programming a neurostimulator may include a storage device and a user interface. The storage device may be configured to store waveform building blocks. The user interface may include a display screen, a user input device, and an interface control circuit. The interface control circuit may include a waveform composer configured to allow for composition of one of more building blocks and composition of a pattern of neurostimulation pulses using selected one or more waveform building blocks. The waveform composer may include a library controller and waveform building block editors. The library controller may be configured to display a library management area on the screen. The displayed library management area allows a user to manage the stored waveform building blocks. The waveform building block editors may each be configured to allow the user to compose a type of the waveform building blocks.
PURPOSE:To prevent trouble, e.g. capping or sticking phenomenon, in tableting without inhibiting the performance of a bath tablet, by using adipic acid and/or alkali metal salt thereof as a lubricant in tableting a foaming bath agent. CONSTITUTION:A foaming bath agent is tableted by using at least one of adipic acid and alkali metal salts thereof as a lubricant using, e.g. the following methods; A raw material mixture containing an organic acid, e.g. citric acid, and an inorganic acid salt, e.g. sodium carbonate, as a foaming principal components is first formed into granules having preferably about 32-100 mesh grain size in a dry granulating machine, and, as necessary, further sorting and grading the granules. About 1-10wt%, preferably 3-6wt% of the above- mentioned lubricant is then added and uniformly mixed with the granules and the resultant mixture is tableted according to the conventional method to give the aimed foaming bath agent. According to this method, the above-mentioned trouble can be prevented in tableting without inhibiting the performance by the lubricant.
Autism Spectrum Disorder (ASD) is a multifactorial disorder involving genetic and environmental factors leading to pathophysiologic symptoms and comorbidities including neurodevelopmental disorders, anxiety, immune dysregulation, and gastrointestinal (GI) abnormalities. Abnormal intestinal permeability has been reported among ASD patients and it is well established that disturbances in eating patterns may cause gut microbiome imbalance (i.e., dysbiosis). Therefore, studies focusing on the potential relationship between gut microbiota and ASD are emerging. We compared the intestinal bacteriome and mycobiome of a cohort of ASD subjects with their non-ASD siblings. Differences between ASD and non-ASD subjects include a significant decrease at the phylum level in Cyanobacteria (0.015% vs. 0.074%, p < 0.0003), and a significant decrease at the genus level in Bacteroides (28.3% vs. 36.8%, p < 0.03). Species-level analysis showed a significant decrease in Faecalibacterium prausnitzii, Prevotella copri, Bacteroides fragilis, and Akkermansia municiphila. Mycobiome analysis showed an increase in the fungal Ascomycota phylum (98.3% vs. 94%, p < 0.047) and an increase in Candida albicans (27.1% vs. 13.2%, p < 0.055). Multivariate analysis showed that organisms from the genus Delftia were predictive of an increased odds ratio of ASD, whereas decreases at the phylum level in Cyanobacteria and at the genus level in Azospirillum were associated with an increased odds ratio of ASD. We screened 24 probiotic organisms to identify strains that could alter the growth patterns of organisms identified as elevated within ASD subject samples. In a preliminary in vivo preclinical test, we challenged wild-type Balb/c mice with Delftia acidovorans (increased in ASD subjects) by oral gavage and compared changes in behavioral patterns to sham-treated controls. An in vitro biofilm assay was used to determine the ability of potentially beneficial microorganisms to alter the biofilm-forming patterns of Delftia acidovorans, as well as their ability to break down fiber. Downregulation of cyanobacteria (generally beneficial for inflammation and wound healing) combined with an increase in biofilm-forming species such as D. acidovorans suggests that ASD-related GI symptoms may result from decreases in beneficial organisms with a concomitant increase in potential pathogens, and that beneficial probiotics can be identified that counteract these changes.
MicroRNAs (miRNAs) are key post-transcriptional regulators of gene expression that have been implicated in a plethora of neuronal processes. Nevertheless, their role in regulating brain activity in the context of sleep has so far received little attention. To test their involvement, we deleted mature miRNAs in post-mitotic neurons at two developmental ages, i.e., in early adulthood using conditional Dicer knockout (cKO) mice and in adult mice using an inducible conditional Dicer cKO (icKO) line. In both models, electroencephalographic (EEG) activity was affected and the response to sleep deprivation (SD) altered; while the rapid-eye-movement sleep (REMS) rebound was compromised in both, the increase in EEG delta (1 to 4 Hz) power during non-REMS (NREMS) was smaller in cKO mice and larger in icKO mice compared to controls. We subsequently investigated the effects of SD on the forebrain miRNA transcriptome and found that the expression of 48 miRNAs was affected, and in particular that of the activity-dependent miR-709. In vivo inhibition of miR-709 in the brain increased EEG power during NREMS in the slow-delta (0.75 to 1.75 Hz) range, particularly after periods of prolonged wakefulness. Transcriptome analysis of primary cortical neurons in vitro revealed that miR-709 regulates genes involved in glutamatergic neurotransmission. A subset of these genes was also affected in the cortices of sleep-deprived, miR-709-inhibited mice. Our data implicate miRNAs in the regulation of EEG activity and indicate that miR-709 links neuronal activity during wakefulness to brain synchrony during sleep through the regulation of glutamatergic signaling.
<P>PROBLEM TO BE SOLVED: To provide a cosmetic for hair having excellent maintainability of hairdressing force and luster without greasiness.  <P>SOLUTION: The cosmetic for hair is obtained by including a (10-30C)alkylacrylate and methacrylate copolymer and/or its salt. Furthermore, an amphoteric polymer is preferably contained as a hairdressing ingredient. A methacrylic acid-N-dimethylaminoethyl methacrylate-acetone acrylamide copolymer can preferably be exemplified as the amphoteric polymer. In addition, a wax is preferably contained. A saturated higher alcohol is preferred as the wax and the 1-5 wt.% content is preferably exemplified.  <P>COPYRIGHT: (C)2004,JPO
A sterilized gel, a preparation method thereof, an ultrasonic coupling agent based on the sterilized gel, and a preparation method and an application of the ultrasonic coupling agent. The invention belongs to the technical field of ultrasonic coupling agents. The invention aims to solve the technical problem that the existing ultrasonic coupling agent is poor in moisture retention and sterilization stability. Preparation of the sterilized gel of the invention: adding acrylic acid, ethyl acrylate, butyl acrylate, AEO-15 and sodium dodecyl sulfate into deionized water, and then adding persulfate, tannic acid and chitosan quaternary ammonium salt to obtain the sterilized gel. Preparing an ultrasonic coupling agent: dissolving the sterilized gel in deionized water; mixing glycerol and polyethylene glycol 1000 uniformly; and mixing the solutions, and adding triethanolamine to obtain the ultrasonic coupling agent. The ultrasonic couplant is used for ultrasonic detection.
The present invention relates to a pharmaceutical composition for preventing and treating bone diseases comprising an extract of Geranium krameri FR. Et SSAV as an active ingredient. The extract of Geranium krameri FR. Et SSAV decreases expression of NFATc1 and c-FOS protein and inhibits activation of ERK and p38 MAPK in a differentiation process into the osteoclasts by RANKL, thereby inhibiting differentiation into osteoclasts and bone resorption by the osteoclasts; inhibiting bone loss by LPS in a bone loss inducing animal model; and significantly reducing the number of osteoclasts. Therefore, the extract of Geranium krameri FR. Et. SSAV can be usefully used as a composition for preventing or treating bone diseases.
<P>PROBLEM TO BE SOLVED: To provide a therapy in the field of immunology, more specifically cancer immunotherapy, and particularly, combined immunotherapy and a therapeutic method for inhibiting growth of tumor cells and/or removing tumor cells.  <P>SOLUTION: The method is based on inhibiting receptors having protein kinase activity in tylosin residues (receptor tyrosine kinase, RTK) and ligands of these receptors. The combined immunotherapy is defined as a treatment for inhibiting the RTK receptors and/or their ligands by the combined use of passive and active immunity therapies. The described procedure can be applied to a patient in various clinical stages of a tumor derived from an epithelium which excessively expresses these receptors. The combined use of active and passive immunity may be performed simultaneously or successively irrespective of whether the treatment procedure is used for a patient in advanced stages of disease or it is used as an auxiliary treatment.  <P>COPYRIGHT: (C)2010,JPO&INPIT
A recombinant fusion protein includes a receptor associated protein 1 (RAP1), a cluster of differentiation 28 (CD28)- Pseudomonas  exotoxin A translocation domain (PEt) fusion polypeptide, a legumain protein and a target peptide. The RAP1 is located at the N-terminus of the recombinant fusion protein. The CD28-PEt fusion polypeptide is located at the C-terminus of the RAP1. The legumain protein is located at the C-terminus of the CD28-PEt fusion polypeptide. The target peptide is located at the C-terminus of the legumain protein. In another embodiment of the present disclosure, an immunogenic composition is provided. The immunogenic composition including the recombinant fusion protein and an adjuvant is used for inducing specific immune responses in a subject with cancer, whereby the risk of cancer metastasis and recurrence for the subject may be successfully reduced.
FIELD: medicine. SUBSTANCE: storage-stable solution contain ethene dissolved in appropriate aqueous liquid of decreased reactivity. The latter is represented by aqueous deionized liquid. Methods for therapy and prophylaxis due to application of ethene-containing solutions includes both direct and indirect action against disease and microorganisms, and, also, methods to improve metabolic functions and either initiation or induction of host organism for the increase of protective response against disease or microorganisms. New ethene-containing solutions demonstrate increased chemical resistance and stability at storage. Ethene level in solution isn't changed considerably during more than one month since the moment of its preparation. Ethene-containing solutions provide sterilizing action and/or inhibiting action upon microorganisms in host organism, even if concrete microorganism isn't directly sensitive to ethene. EFFECT: improved results in therapy and prophylaxis. 36 cl, 2 dwg, 1 tbl
The initial dose of nifedipine will be 2 × 10 mg nifedipine capsules orally in the first hour, followed by 20 mg slow-release nifedipine every 6 hours for the next 47 hours. In the first hour after starting nifedipine, blood pressure and heart rate will be measured every 15 minutes. If blood pressure remains within the normal limits, treatment will be continued.
The invention belongs to the field of traditional Chinese medicine pharmacy, and specifically relates to plaster for treating bone fracture and a preparation method of the plaster. The plaster is prepared from the following raw materials, by weight part, coarse traditional Chinese medicine materials, fine traditional Chinese medicine materials, vegetable oil, and minium. The adopted traditional Chinese medicine materials conform to regulations of Pharmacopoeia of the People's Republic of China and are safe and reliable. The medicines match each other and have the efficacy of activating blood and resolving stasis, dispersing swelling and relieving pain, relaxing sinews and regulating qi, dissipating cold and dispelling wind, and conducting union of fractured tendons and bones. The plaster can treat bone fracture, has a precise and fast curative effect, and is high in cure rate and free of side effect. The plaster is applied to: 1, all kinds of organic lesions about bones and joints, such as various kinds of arthritis, periarthritis humeroscapularis, cervical spondylosis, hyperosteogeny, and bony spurs; 2, all kinds of traumatic skin, bone, tendon and vessel lesions, such as various kinds of wounds, bone fracture, and tendon and vessel clonus; and 3, muscle strain lesions at all parts, such as waist soreness and backache, and cervicobrachial (muscle) pain.
Patients with myocardial ischemia and infarction are at increased risk of arrhythmias, which in turn, can exacerbate the overall risk of mortality. Despite the observed reduction in recurrent arrhythmias through antiarrhythmic drug therapy, the precise mechanisms underlying their effectiveness in treating ischemic heart disease remain unclear. Moreover, there is a lack of specialized drugs designed explicitly for the treatment of myocardial ischemic arrhythmia. This study employs an electrophysiological simulation approach to investigate the potential antiarrhythmic effects and underlying mechanisms of various pharmacological agents in the context of ischemia and myocardial infarction (MI). Based on physiological experimental data, computational models are developed to simulate the effects of a series of pharmacological agents (amiodarone, telmisartan, E-4031, chromanol 293B, and glibenclamide) on cellular electrophysiology and utilized to further evaluate their antiarrhythmic effectiveness during ischemia. On 2D and 3D tissues with multiple pathological conditions, the simulation results indicate that the antiarrhythmic effect of glibenclamide is primarily attributed to the suppression of efflux of potassium ion to facilitate the restitution of [K+]o, as opposed to recovery of IKATP during myocardial ischemia. This discovery implies that, during acute cardiac ischemia, pro-arrhythmogenic alterations in cardiac tissue's excitability and conduction properties are more significantly influenced by electrophysiological changes in the depolarization rate, as opposed to variations in the action potential duration (APD). These findings offer specific insights into potentially effective targets for investigating ischemic arrhythmias, providing significant guidance for clinical interventions in acute coronary syndrome.
After an initial assessment to confirm eligibility, the experimental group will receive 8 weekly sessions (2 hours long) of our augmented group CBT for perinatal anxiety during a global pandemic (n=6 per group). Participants will be re-assessed at post-treatment and at a 3-month follow-up to determine the effectiveness of the treatment and whether these effects are maintained in the long-term.
OBJECTIVES: I. Determine the response rate of patients with locally recurrent carcinoma of the head and neck or lung treated with paclitaxel and cisplatin with concurrent radiotherapy followed by filgrastim (G-CSF). II. Assess the toxicity of this regimen in these patients. III. Determine the time to progression and the sites and pattern of progression in patients treated with this regimen. IV. Determine the median, 1-year, and 2-year survival rates of patients treated with this regimen.

OUTLINE: This is a multicenter study. Patients are stratified according to disease (squamous cell carcinoma of the head and neck vs salivary gland malignancy or other non-squamous cell carcinoma of the head and neck vs lung cancer). Patients receive paclitaxel IV over 1 hour and cisplatin IV over 30-120 minutes on days 1-5. Patients undergo radiotherapy twice daily on days 1-5. Patients receive filgrastim (G-CSF) subcutaneously on days 6-13 or until blood counts recover. Treatment repeats every 2 weeks for a total of 4 courses in the absence of unacceptable toxicity or disease progression. Patients are followed every 2 months.

PROJECTED ACCRUAL: A total of 42-84 patients (14-28 per stratum) will be accrued for this study within 2-4 years.
Antibodies or antigen binding fragments thereof that specifically bind to PV-1 protein and uses thereof are disclosed. The antibody or antigen binding fragment thereof comprises a heavy chain variable region and a light chain variable region, the determinant complementary regions of the heavy chain variable region and the light chain variable region each consisting of CDR1, CDR2 and CDR 3; the amino acid sequence of CDR1 of heavy chain variable region is shown in 26-35 positions of SEQ ID NO. 5, etc.; the amino acid sequence of CDR2 of heavy chain variable region is shown in 50-66 positions of SEQ ID NO. 5, etc.; the amino acid sequence of CDR3 of heavy chain variable region is shown in 97-101 positions of SEQ ID NO. 5, etc.; the amino acid sequence of CDR1 of the light chain variable region is shown in positions 24-34 of SEQ ID NO. 15 and the like; the amino acid sequence of CDR2 of the light chain variable region is shown in positions 50-56 of SEQ ID NO. 15 and the like; the amino acid sequence of CDR3 of the light chain variable region is shown in positions 89-97 of SEQ ID NO. 15, etc. The affinity of the antibody or antigen binding fragment thereof is improved by 1-2 orders of magnitude compared with that of the original antibody, and the theory can reduce the dosage and accelerate the clinical drug development of new PV-1 targets.
The exercise intervention will consist of 24 supervised, heavy lifting strength training exercise sessions over a 12 week period. The exercise frequency will be two times per week. Main exercises will consist of barbell back squat, bench press, and dead lift.
All patients will undergo endoscopic retrograde cholangiopancreatography (ERCP) that is indicated for suspected or confirmed choledocholithiasis or biliary strictures. "Air" contrast cholangiography using carbon dioxide gas will be performed with standard fluoroscopy and digital subtraction fluoroscopic image capture followed by routine cholangiography using iodinated contrast and standard fluoroscopy. Carbon dioxide (CO2) is routinely used in ERCP procedures and would flow into the biliary tree of patients at the time of ERCP, irrespective of this study's interventions. Digital subtraction image capture is a commercially available setting on certain fluoroscopy units that optimizes resolution with air or CO2 used as a contrast medium.
Humira® (adalimumab Prefilled Syringe produced by AbbVie Company) 40 mg/0.8 ml Every other week 40 mg Adalimumab, will be subcutaneously administered to rheumatic patients during six months. Along with, 15 mg weekly methotrexate, at least 1 mg daily Folic acid and 7.5 mg daily Prednisolone over six months.
When cells are stressed, DNA from energy-producing mitochondria can leak out and drive inflammatory immune responses if not cleared. Cells employ a quality control system called autophagy to specifically degrade damaged components. We discovered that mitochondrial transcription factor A (TFAM)-a protein that binds mitochondrial DNA (mtDNA)-helps to eliminate leaked mtDNA by interacting with the autophagy protein LC3 through an autolysosomal pathway (we term this nucleoid-phagy). TFAM contains a molecular zip code called the LC3 interacting region (LIR) motif that enables this binding. Although mutating TFAM's LIR motif did not affect its normal mitochondrial functions, more mtDNA accumulated in the cell cytoplasm, activating inflammatory signalling pathways. Thus, TFAM mediates autophagic removal of leaked mtDNA to restrict inflammation. Identifying this mechanism advances understanding of how cells exploit autophagy machinery to selectively target and degrade inflammatory mtDNA. These findings could inform research on diseases involving mitochondrial damage and inflammation.
Four placebo-controlled dose response studies were conducted using once-daily oral dosing of MAVIK in doses from 0.25 to 16 mg per day in 827 black and non-black patients with mild to moderate hypertension. The minimal effective once-daily dose was 1 mg in non-black patients and 2 mg in black patients. Further decreases in trough supine diastolic blood pressure were obtained in non-black patients with higher doses, and no further response was seen with doses above 4 mg (up to 16 mg). The antihypertensive effect diminished somewhat at the end of the dosing interval, but trough/peak ratios are well above 50% for all effective doses. There was a slightly greater effect on the diastolic pressure, but no difference on systolic pressure with b.i.d. dosing. During chronic therapy, the maximum reduction in blood pressure with any dose is achieved within one week. Following 6 weeks of monotherapy in placebo-controlled trials in patients with mild to moderate hypertension, once-daily doses of 2 to 4 mg lowered supine or standing systolic/diastolic blood pressure 24 hours after dosing by an average 7-10/4-5 mmHg below placebo responses in non-black patients. Once-daily doses of 2 to 4 mg lowered blood pressure 4-6/3-4 mmHg in black patients. Trough to peak ratios for effective doses ranged from 0.5 to 0.9. There were no differences in response between men and women, but responses were somewhat greater in patients under 60 than in patients over 60 years old. Abrupt withdrawal of MAVIK has not been associated with a rapid increase in blood pressure.

Administration of MAVIK to patients with mild to moderate hypertension results in a reduction of supine, sitting and standing blood pressure to about the same extent without compensatory tachycardia.

Symptomatic hypotension is infrequent, although it can occur in patients who are salt- and/or volume-depleted. (see WARNINGS.) Use of MAVIK in combination with thiazide diuretics gives a blood pressure lowering effect greater than that seen with either agent alone, and the additional effect of trandolapril is similar to the effect of monotherapy.